Our Science

Montis Biosciences is a preclinical-stage biopharmaceutical company advancing innovative therapeutics to treat inflammation-driven neurodegenerative diseases, autoimmune disorders and selected cancers. Leveraging its patient-centric discovery platform, Montis is advancing unique and potent antibodies to bring new treatment options to those patients.

Montis’ lead program, MB01, focuses on modulating the multifaceted roles of C1q, the activator of the classical complement pathway and a key immune system mediator in neuroinflammatory and autoimmune disorders. 

Unlike existing classical complement targeting approaches that focus on blocking the classical complement pathway, Montis has discovered novel anti-C1q antibodies, capable of modulating C1q’s complement-independent functions with or without inhibiting the classical complement cascade. These antibodies hold the potential to offer a paradigm shift in the complement field and to revolutionize treatments for certain neurodegenerative diseases and autoimmune neuropathies. Based on extensive in vitro end in vivo evaluation, Montis has selected potent the drug candidates and is working to advance them to IND enabling work and clinical evaluation in diseases of high unmet medical need.

Montis’ second program (MB02) focuses on inhibiting CD93, a novel perivascular target, in lung squamous cell carcinoma (LUSC). A potent drug candidate was selected, holding best-in-class potential in this inflammation-driven and underserved oncology indication. Montis plans to partner this promising asset.

Montis is backed by a strong investor syndicate, including Droia Ventures, Pfizer Ventures, Polaris Innovation Fund, ALSA Ventures and VIB, and is led by a team with extensive drug development experience.